FDA approves expanded use of BeiGene's blood cancer drug

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 07, 2024 at 05:32: PM
via The U.S. Food and Drug Administration has granted accelerated approval for the expanded use of BeiGene's (6160.HK) combination drug to treat certain patients with a type of blood cancer, the health regulator said on Thursday.

article source
 

<



Similar threads

cafead
FDA approves expanded use of Bristol Myers&#039; cancer cell therapy
Replies
0
Views
65
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA approves expanded use of Mirum&#039;s liver disease drug
Replies
0
Views
148
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA approves expanded indication for Supernus’ Qelbree for ADHD
Replies
0
Views
181
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA approves expanded indication for UCB’s Briviact to treat pediatric patients
Replies
0
Views
95
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA approves expanded use of Jazz Pharma&#039;s sleep disorder drug Xywav
Replies
0
Views
109
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote